Gilead's HIV portfolio soars, but is it enough to combat falling HCV sales?
admin 26th October 2018 Uncategorised 0Gilead’s third-quarter results offered a glimmer of hope for continued growth—particularly in HIV—but Wall Street skeptics weren’t convinced. Its personalized CAR-T cancer therapy Yescarta has been slow to catch on, and one potentially lucrative pipeline prospect could be held up by the FDA’s safety concerns.
More: Gilead's HIV portfolio soars, but is it enough to combat falling HCV sales?
Source: fierce